Calendrier des promotions Edesa Biotech, Inc.
Calendrier avancé
Graphique simple
À propos de l'entreprise Edesa Biotech, Inc.
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that is in Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.Paramètres de base
IPO date
2015-11-05
ISIN
CA27966L1085
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
Grade
Sous-estimation
Nom | Signification | Grade |
P/S | 0 | 0 |
P/BV | 7.18 | 1 |
P/E | 0 | 0 |
Efficacité
Nom | Signification | Grade |
ROA | -97.13 | 0 |
ROE | -136.66 | 0 |
ROIC | 0 | 0 |
Dividendes
Nom | Signification | Grade |
Rendement en dividendes | 0 | 0 |
DSI | 0 | 0 |
Croissance moyenne du dividende | 0 | 0 |
Devoir
Nom | Signification | Grade |
Debt/EBITDA | -0.0033 | 10 |
Debt/Ratio | 0.0052 | 10 |
Debt/Equity | 0.9251 | 9 |
Impulsion de croissance
Nom | Signification | Grade |
Rentabilité Revenue, % | 44.12 | 6 |
Rentabilité Ebitda, % | -6.51 | 0 |
Rentabilité EPS, % | 160.98 | 10 |
paper.price.prices
Prix | Common.min. | Common.max. | Changement | paper.changes_in_industry | paper.changes_in_index | |
common.calendar.number_days.1 | 1.92 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
common.calendar.number_days.7d | 1.86 $ | 0 $ | 0 $ | 3.23 % | 0 % | 0 % |
common.calendar.number_days.30d | 1.96 $ | 1.83 $ | 1.96 $ | -2.04 % | 0 % | 0 % |
common.calendar.number_days.90d | 2.25 $ | 1.83 $ | 2.4 $ | -14.67 % | 0 % | 0 % |
common.calendar.number_days.180d | 1.91 $ | 1.59 $ | 3.25 $ | 0.52 % | 0 % | 0 % |
common.calendar.number_days.1y | 4.34 $ | 1.59 $ | 5.42 $ | -55.76 % | 0 % | 0 % |
common.calendar.number_days.3y | 1.9 $ | 0.77 $ | 30.63 $ | 1.05 % | 0 % | 0 % |
common.calendar.number_days.5y | 7.07 $ | 0.77 $ | 30.63 $ | -72.84 % | 0 % | 0 % |
common.calendar.number_days.10y | 0.53 $ | 0.53 $ | 30.63 $ | 362.26 % | 0 % | 0 % |
common.calendar.number_days.ytd | 1.95 $ | 1.59 $ | 3.25 $ | -1.54 % | 0 % | 0 % |
Principaux propriétaires
Entreprises similaires
P/E & P/BV
Gestion d'entreprise
Superviseur | Titre d'emploi | Paiement | Année de naissance |
Dr. Pardeep Nijhawan FRCPC, M.D. | CEO, Company Secretary & Director | 475.33k | 1971 (54 année) |
Dr. Michael J. Brooks M.B.A., Ph.D. | President | 439.27k | 1978 (47 années) |
Mr. Stephen L. Lemieux BA, CPA, CA, CPA, MMPA | Chief Financial Officer | 402.86k | 1977 (48 années) |
Informations sur l'entreprise
Adresse: Canada, Markham. ON LR H, 100 Spy Court - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.edesabiotech.com
Site web: https://www.edesabiotech.com